Figure 1.
Flow chart of the different patients group according to C-reactive protein (CRP) kinetics.
Figure 2.
The relationship between the baseline serum C-reactive protein and plasma EBV-DNA copy.
(A) Correlation between baseline serum C-reactive protein and plasma EBV-DNA copy (P < 0.0001, r = 0.352). (B)The plasma EBV-DNA copy of NPC patients with higher baseline CRP levels was significantly higher than those with lower baseline CRP levels (P = 0.0001).
Figure 3.
Kaplan-Meier analysis of overall survival according to baseline C-reactive protein (CRP) levels.
(A) Overall survival in all patients according to baseline CRP levels (P < 0.0001). (B) Kaplan-Meier analysis of overall survival in one metastasis subgroup (P = 0.003). (C) Kaplan-Meier analysis of overall survival in multiple metastasis sites subgroup (P = 0.001). (D) Kaplan-Meier analysis of overall survival in metastasis after radical therapy subgroup (P = 0.007). (E) Kaplan-Meier analysis of overall survival in metastasis at presentation subgroup (P = 0.004). (F) Kaplan-Meier analysis of overall survival in bone metastasis subgroup (P = 0.0001). (G) Kaplan-Meier analysis of overall survival in liver subgroup (P = 0.003). (H) Kaplan-Meier analysis of overall survival in lung subgroup. The log-rank test was used to calculate P-values (P = 0.168).
Figure 4.
Kaplan-Meier analysis of the overall survival regarding CRP kinetics.
Kaplan-Meier analysis of overall survival of non-elevated (CRP < 3.4 mg/L and never elevated during treatment), elevated (CRP < 3.4 mg/L and elevated at least one time during treatment), normalized (CRP ≥ 3.4 mg/L and normalized at least one time during treatment) and non-normalized (CRP ≥ 3.4 mg/L and never normalized during treatment) groups patients with metastasis nasopharyngeal carcinoma (P < 0.0001).